DK83388A - Farmaceutisk middel indeholdende den insulin-lignende vaekstfaktor ii (igf-ii) til topisk anvendelse til saarheling - Google Patents

Farmaceutisk middel indeholdende den insulin-lignende vaekstfaktor ii (igf-ii) til topisk anvendelse til saarheling

Info

Publication number
DK83388A
DK83388A DK083388A DK83388A DK83388A DK 83388 A DK83388 A DK 83388A DK 083388 A DK083388 A DK 083388A DK 83388 A DK83388 A DK 83388A DK 83388 A DK83388 A DK 83388A
Authority
DK
Denmark
Prior art keywords
igf
insulin
pharmaceutical composition
growth factor
composition containing
Prior art date
Application number
DK083388A
Other languages
English (en)
Other versions
DK83388D0 (da
Inventor
Carl Joseph Shaar
Michele Ceceil Smith
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DK83388D0 publication Critical patent/DK83388D0/da
Publication of DK83388A publication Critical patent/DK83388A/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0066—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/008—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Materials Engineering (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DK083388A 1987-02-24 1988-02-18 Farmaceutisk middel indeholdende den insulin-lignende vaekstfaktor ii (igf-ii) til topisk anvendelse til saarheling DK83388A (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/018,251 US4885163A (en) 1987-02-24 1987-02-24 Topical use of IGF-II for wound healing

Publications (2)

Publication Number Publication Date
DK83388D0 DK83388D0 (da) 1988-02-18
DK83388A true DK83388A (da) 1988-08-25

Family

ID=21786996

Family Applications (1)

Application Number Title Priority Date Filing Date
DK083388A DK83388A (da) 1987-02-24 1988-02-18 Farmaceutisk middel indeholdende den insulin-lignende vaekstfaktor ii (igf-ii) til topisk anvendelse til saarheling

Country Status (11)

Country Link
US (1) US4885163A (da)
EP (1) EP0280460A3 (da)
JP (1) JPS63233925A (da)
KR (1) KR880009662A (da)
AU (1) AU610127B2 (da)
DK (1) DK83388A (da)
HU (1) HU200423B (da)
IL (1) IL85426A0 (da)
NZ (1) NZ223520A (da)
PH (1) PH25514A (da)
ZA (1) ZA881037B (da)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200509A (en) * 1987-04-06 1993-04-06 Celtrix Pharmaceuticals, Inc. Human somatomedin carrier protein subunits and process for producing them; recombinant DNA molecules, hosts, processes and human somatomedin carrier protein-like polypeptides
EP0289314B1 (en) * 1987-04-28 1994-10-12 Roche Diagnostics GmbH Use of IGF-II in the treatment of bone disorders
NZ226171A (en) * 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
GB8806893D0 (en) * 1988-03-23 1988-04-27 Unilever Plc Cosmetic composition
US5256644A (en) * 1988-05-20 1993-10-26 Institute Of Molecular Biology, Inc. Wound healing using IGF-II and TGF
US5654267A (en) * 1988-12-20 1997-08-05 La Jolla Cancer Research Center Cooperative combinations of ligands contained within a matrix
IL92816A0 (en) * 1988-12-22 1990-09-17 Biogrowth Inc Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides
US5145679A (en) * 1989-10-05 1992-09-08 Hinson Joan B Topical emollient for prevention and treatment of circulatory induced lesions
GB8927008D0 (en) * 1989-11-29 1990-01-17 Ciba Geigy Novel process for the production of unfused protein in e.coli
ES2106031T3 (es) * 1990-04-10 1997-11-01 Inst Molecular Biology Inc Una composicion comprendiendo un factor de crecimiento, su metodo de obtencion y uso.
CA2082420C (en) * 1990-05-30 2004-07-20 Harry N. Antoniades Wound healing composition comprising purified igf-i or igf-ii and a purified tgf-.beta.
US6004775A (en) * 1990-08-03 1999-12-21 The Salk Institute For Biological Studies DNA encoding IGFBP-4
SE9101840L (sv) * 1991-06-14 1992-12-15 Kabi Pharmacia Ny medicinsk anvaendning
AU2368892A (en) * 1991-07-29 1993-03-02 British Bio-Technology Limited Igf-ii analogues
WO1993010795A1 (en) * 1991-11-27 1993-06-10 Hinson Joan B Topical emollient for prevention and treatment of circulatory induced lesions
CA2137275A1 (en) * 1992-06-03 1993-12-09 Richard L. Eckert Bandage for continuous application of biologicals
JPH06510065A (ja) * 1992-06-08 1994-11-10 カイロン　コーポレーション 成長因子ｉｇｆ−ｉおよび／またはｉｇｆ−ｉｉの用法
PT871730E (pt) 1995-10-11 2004-11-30 Chiron Corp Combinacao de pdgf, kgf, igf e igfbp para cicatrizacao de ferimentos
JP3191038B2 (ja) 1996-06-26 2001-07-23 輝夫 西田 眼科用医薬組成物
US20020136712A1 (en) * 1997-10-31 2002-09-26 Fischetti Vincent Bacterial phage associated lysing enzymes for the prophylactic and therapeutic treatment of colonization and infections caused by streptococcus pneumoniae
US6056954A (en) 1997-10-31 2000-05-02 New Horizons Diagnostics Corp Use of bacterial phage associated lysing enzymers for the prophylactic and therapeutic treatment of various illnesses
US6277399B1 (en) 1997-10-31 2001-08-21 New Horizon Diagnostics Corporation Composition incorporating bacterial phage associated lysing enzymes for treating dermatological infections
US6406692B1 (en) * 1997-10-31 2002-06-18 New Horizons Diagnostics Corp Composition for treatment of an ocular bacterial infection
US20030082110A1 (en) * 1997-10-31 2003-05-01 Vincent Fischetti Use of bacterial phage associated lysing proteins for treating bacterial dental caries
US6399097B1 (en) * 1997-10-31 2002-06-04 New Horizons Diagnostics Corporation Composition for treatment of a bacterial infection of the digestive tract
US6423299B1 (en) * 1997-10-31 2002-07-23 Vincent Fischetti Composition for treatment of a bacterial infection of an upper respiratory tract
US20030129146A1 (en) * 1997-10-31 2003-07-10 Vincent Fischetti The use of bacterial phage associated lysing proteins for treating bacterial dental caries
US6399098B1 (en) 1997-10-31 2002-06-04 New Horizons Diagnostics Corp Composition for treating dental caries caused by streptococcus mutans
US20030129147A1 (en) * 1997-10-31 2003-07-10 Vincent Fischetti Use of bacterial phage associated lysing proteins for treating bacterial dental caries
US6428784B1 (en) * 1997-10-31 2002-08-06 New Horizons Diagnostics Corp Vaginal suppository for treating group B Streptococcus infection
US7232576B2 (en) 1997-10-31 2007-06-19 New Horizons Diagnostics Corp Throat lozenge for the treatment of Streptococcus Group A
US6432444B1 (en) * 1997-10-31 2002-08-13 New Horizons Diagnostics Corp Use of bacterial phage associated lysing enzymes for treating dermatological infections
US6752988B1 (en) * 2000-04-28 2004-06-22 New Horizons Diagnostic Corp Method of treating upper resiratory illnesses
US6372494B1 (en) * 1999-05-14 2002-04-16 Advanced Tissue Sciences, Inc. Methods of making conditioned cell culture medium compositions
US20020127215A1 (en) * 1999-09-14 2002-09-12 Lawrence Loomis Parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections
US7063837B2 (en) * 1999-09-14 2006-06-20 New Horizons Diagnostics Corp Syrup composition containing phage associated lytic enzymes
US20020187136A1 (en) * 2000-04-28 2002-12-12 Lawrence Loomis Use of bacterial phage associated lysing enzymes for treating various illnesses
US20040037828A1 (en) * 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
DE60142341D1 (de) * 2000-08-10 2010-07-22 Santen Pharmaceutical Co Ltd Förderer der Hautwundheilung
US6395504B1 (en) 2000-09-01 2002-05-28 New Horizons Diagnostics Corp. Use of phage associated lytic enzymes for the rapid detection of bacterial contaminants
CA2427928A1 (en) * 2000-11-02 2002-12-27 New Horizons Diagnostics Corporation The use of bacterial phage associated lytic enzymes to prevent food poisoning
GB2369572A (en) * 2000-11-29 2002-06-05 Raft Trustees Ltd Wound treatment composition comprising insulin
US20040213765A1 (en) * 2001-07-13 2004-10-28 Vincent Fischetti Use of bacterial phage associated lytic enzymes to prevent food poisoning
TWI305778B (en) * 2001-12-03 2009-02-01 Nishida Teruo Peptides of an expressing unit for igf-i minimal activity and their pharmaceutical use
WO2005013885A2 (en) 2003-08-07 2005-02-17 Healor Ltd. Pharmaceutical compositions and methods for accelerating wound healing
EP2452686A3 (en) 2005-08-29 2012-09-05 HealOr Ltd. Methods and compositions for prevention and treatment of diabetic and aged skin
US8940868B2 (en) * 2009-10-08 2015-01-27 The General Hospital Corporation Elastin based growth factor delivery platform for wound healing and regeneration
EP2523677A2 (en) 2010-01-11 2012-11-21 Healor Ltd. Method for treatment of inflammatory disease and disorder
US20160243023A1 (en) * 2015-02-19 2016-08-25 Elc Management Llc Novel Skin Remodeling Strategy
CN106167789B (zh) * 2015-05-21 2020-08-04 中国科学院上海营养与健康研究所 低氧处理的间充质干细胞及其应用
SG11202103696XA (en) 2018-10-26 2021-05-28 Alkahest Inc Use of plasma and plasma fractions for improvement of pain, wound healing, and postoperative recovery

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2428412A1 (de) * 1974-06-12 1976-01-15 Hoechst Ag Verfahren zur herstellung von insulin, insulin-analogen und -derivaten
DE3382562D1 (de) * 1982-09-24 1992-06-25 Us Health Wiederherstellung von gewebe bei tieren.
US4444683A (en) * 1982-11-17 1984-04-24 University Of Utah Glycosylated insulin derivatives
CA1275922C (en) * 1985-11-28 1990-11-06 Harunobu Amagase Treatment of cancer
US4963665A (en) * 1986-01-07 1990-10-16 Washington University Human preproinsulin-like growth factor I
ATE88899T1 (de) * 1986-11-14 1993-05-15 Inst Molecular Biology Inc Wundheilung und knochenregeneration.
DE58906966D1 (de) * 1988-06-23 1994-03-24 Hoechst Ag Mini-Proinsulin, seine Herstellung und Verwendung.

Also Published As

Publication number Publication date
HUT46231A (en) 1988-10-28
ZA881037B (en) 1989-10-25
HU200423B (en) 1990-06-28
PH25514A (en) 1991-07-24
DK83388D0 (da) 1988-02-18
AU1197288A (en) 1988-08-25
AU610127B2 (en) 1991-05-16
JPS63233925A (ja) 1988-09-29
KR880009662A (ko) 1988-10-04
EP0280460A3 (en) 1990-06-06
IL85426A0 (en) 1988-07-31
US4885163A (en) 1989-12-05
EP0280460A2 (en) 1988-08-31
NZ223520A (en) 1990-04-26

Similar Documents

Publication Publication Date Title
DK83388D0 (da) Farmaceutisk middel indeholdende den insulin-lignende vaekstfaktor ii (igf-ii) til topisk anvendelse til saarheling
DK531885D0 (da) Fremgangsmaade til desinfektion og middel dertil
DE3579655D1 (de) Arzneimittel zur externen anwendung enthaltend aktives vitamin-d3.
DE3480599D1 (de) 1-hydroxypyrid-2-on-derivate enthaltende pharmazeutische zubereitungen.
DK187687A (da) Fungicide forbindelser og fremgangsmaade til fremstilling deraf, midler indeholdende forbindelserne og disses anvendelse
DK332086D0 (da) Fremgangsmaade til rensning af faktor viii.c og farmaceutisk middel indeholdende faktor viii.c
FI812810A7 (fi) Ammoniometyyliyhdisteitä, menetelmiä niiden valmistamiseksi, näitä yhdisteitä sisältäviä farmaseuttisia valvalmisteita ja viimemainittujen käyttö.
DE3866376D1 (de) Cyclohexanabkoemmling und ihn enthaltende fluessigkristallzusammensetzung.
FI863971A7 (fi) Farmaseuttinen koostumus käytettäväksi leukopenian hoidossa.
DK279085A (da) Saede til stol
DK160150C (da) Benzothiazinderivater, fremgangsmaade til fremstilling heraf og farmaceutiske praeparater indeholdende samme
DK531387D0 (da) 3-propenylcephemderivater, mellemprodukter til anvendelse ved fremstillingen heraf og praeparater indeholdende foerstnaevnte forbindelser.
FI831926A7 (fi) (+)-syanidan-3-olijohdannaisia sisältävät farmaseuttiset valmisteet ja niiden käyttö, uudet substituosubstituoidut (+)-syanidan-3-oli- johdannaiset ja menetelmät niiden vavalmistamiseksi.
DK334282A (da) Medicinsk komposition samt fremgangsmaade og middel til dens fremstilling
NO860733L (no) N-(2-klor-4-trifluormethylfenyl)-3-trifluormethyl-benzensulfonamidderivat, fremgangsmaate for fremstilling av dette, og fungicid middel inneholdende dette.
DK164865C (da) Silibininderivater, fremgangsmaade til fremstilling deraf samt farmaceutisk middel indeholdende silibininderivaterne
DK133587A (da) 2-heterocyclylthio-penemer, deres anvendelse og farmaceutisk komposition indeholdende forbindelserne
DK396385D0 (da) 2,3-dihydro-1h-indenderivater,fremgangsmaade til fremstilling heraf og farmaceutiske praeparater indeholdende disse forbindelser
IT8522773A0 (it) Composizione farmaceutica contenente fosfocreatina e metodo per preparla.
DK617684D0 (da) 1,3-dioxolanylderivater, fremgangsmaade til deres fremstilling, deres anvendelse og laegemidler indeholdende disse forbindelser
IT8224575A0 (it) Derivati dell'azolil-pentene procedimento di preparazione ditali composti e mezzi biocidi contenenti gli stessi.
FI812536A7 (fi) Uusia diaryyli-imidatsoli-yhdisteitä, menetelmiä niiden valmistamiseksi, näitä yhdisteitä sisältäviä farmasefarmaseuttisia valmisteita ja niiden käyttö.
DK492289A (da) 3-aryloxymethyl-cephalosporinderivater og fremgangsmaade til fremstilling deraf samt farmaceutisk middel indeholdende derivaterne
DK165789C (da) 4-oxo-4h-pyrimidooe2,1,aaaisoquinolinderivater, analogifremgangsmaade til fremstilling deraf, farmaceutisk praeparat indeholdende disse samt derivaterne til anvendelse som antiallergisk middel
FI831927A7 (fi) (+)-syanidan-3-oli- johdannaiset, menetelmät niiden valmistamiseksi, näitä yhdisteitä sisältävät farmasefarmaseuttiset valmisteet ja niiden käyttö.

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment